Island Pharmaceuticals (ASX:ILA) Gross Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ILA Island Pharmaceuticals Ltd ASX:ILA
33 GF Score
Price A$0.47
! 2 Warning Signs
View Full Analysis

What is Island Pharmaceuticals Gross Margin %?

Island Pharmaceuticals ASX:ILA -2.08% 33 Gross Margin % is 0.00% as of Dec. 2025. GuruFocus rates ASX:ILA with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 732 Biotechnology companies, Island Pharmaceuticals ranks worse than 136611.89% on this metric.

Gross Margin % is calculated as gross profit divided by its revenue. Island Pharmaceuticals's Gross Profit for the six months ended in Dec. 2025 was A$0.00 Mil. Island Pharmaceuticals's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Island Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2025 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Island Pharmaceuticals's Gross Margin % or its related term are showing as below:


ASX:ILA's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.905
* Ranked among companies with meaningful Gross Margin % only.

Island Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Island Pharmaceuticals was 0.00% per year.


Island Pharmaceuticals  (ASX:ILA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Island Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Island Pharmaceuticals Gross Margin % Related Terms


Island Pharmaceuticals Gross Margin % Historical Data

* Premium members only.

The historical data trend for Island Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Island Pharmaceuticals Gross Margin % Chart

Island Pharmaceuticals Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Gross Margin %
0.00 0.00 0.00 0.00 0.00

Island Pharmaceuticals Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:ILA vs VRTX, REGN, ALNY: Gross Margin % Comparison

For the Biotechnology subindustry, Island Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Island Pharmaceuticals Gross Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Island Pharmaceuticals's Gross Margin % falls into.


ASX:ILA
33GF Score
Island Pharmaceuticals Ltd ASX:ILA
Gross Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Island Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Island Pharmaceuticals's Gross Margin for the fiscal year that ended in Jun. 2025 is calculated as

Gross Margin % (A: Jun. 2025 )=Gross Profit (A: Jun. 2025 ) / Revenue (A: Jun. 2025 )
=0.1 / 0.109
=(Revenue - Cost of Goods Sold) / Revenue
=(0.109 - 0) / 0.109
=N/A %

Island Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2025 is calculated as


Gross Margin % (Q: Dec. 2025 )=Gross Profit (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Margin % →
What does a Gross Margin % of 0.00% mean?
Island Pharmaceuticals (ASX:ILA) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Island Pharmaceuticals and its competitors. According to the industry distribution chart, Island Pharmaceuticals ranks #999999 out of 732 companies in the Biotechnology industry.
Is Island Pharmaceuticals' Gross Margin % too high?
Island Pharmaceuticals' current Gross Margin % is 0.00%. Based on the distribution chart, Island Pharmaceuticals ranks #999999 out of 732 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Island Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Island Pharmaceuticals ranks #999999 out of 732 companies for Gross Margin %. This places Island Pharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 60.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Island Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Island Pharmaceuticals's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Island Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Island Pharmaceuticals Business Description

Address c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
33GF Score

Get the complete analysis for ASX:ILA

Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.47
Price